News und Analysen
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
EQS-News: RHÖN-KLINIKUM AG increases consolidated profit and revenues
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
3 Things About Invitae Every Smart Investor Knows
Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and
Is Novocure Stock a Buy?
Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it.
Medical device specialist
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q3 2023 Earnings CallNov 01, 2023, 5:00 p.m. ET
Operator
Source Fool.com
ECU Health and Acadia Healthcare Host Groundbreaking Ceremony for New Behavioral Health Hospital
ECU Health and Acadia Healthcare held a ceremony today to celebrate the start of construction on its previously announced state-of-the-art, 144-bed behavioral health hospital in Greenville, North
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q3 2023 Earnings CallNov 01, 2023, 8:00 a.m. ET
Operator
Source Fool.com
EQS-News: Evotec SE to announce results for the first nine months 2023 on 08 November 2023
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent
Why Blueprint Medicines Stock Soared Today
Shares of Blueprint Medicines (NASDAQ: BPMC) closed up 25.6% on Thursday after the cancer and blood discorder therapy company announced stronger-than-expected quarterly results.
Blueprint Medicines'
Acadia Healthcare Welcomes Dr. Patrice A. Harris, MD, MA as Independent Director
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Dr. Patrice A. Harris, MD, MA has been appointed to the Company’s Board of Directors effective October 26, 2023.
This press
Why Novocure Stock Was Sick Today
Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its
Why Alkermes Stock Is Sinking Today
Shares of Alkermes (NASDAQ: ALKS) were sinking 7.9% as of 11:58 a.m. ET on Wednesday and had fallen as much as 13.1% earlier in the session. The decline came after the Ireland-based drugmaker
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Why LianBio Stock Is Skyrocketing Today
Shares of LianBio (NASDAQ: LIAN) were skyrocketing 132.4% higher as of 11:11 a.m. ET on Tuesday. The huge gain came after the company announced that it entered into an agreement to hand over